Novartis Inks Chinese mRNA-Therapy Deal for Up to $7.8 Billion

Novartis AG has entered into a licensing agreement with China's Abogen Biosciences to acquire a messenger RNA-based autoimmune therapy. The financial terms of this strategic deal are valued at up to $7.8 billion. This partnership focuses on leveraging mRNA technology to develop treatments for autoimmune conditions, marking a significant investment by Novartis into the Chinese biotechnology sector to expand its therapeutic pipeline through the acquisition of innovative mRNA-based medical solutions from Abogen Biosciences.